Skip to main content
. 2021 Aug 28;1(2):129–146. doi: 10.1016/j.jacasi.2021.08.003

Figure 1.

Figure 1

Forest Plot of End Points for Asians Versus Whole Study Population

Clinical trials with positive findings are shown. In general, the efficacy of GLP-1 receptor agonists and SGLT2 inhibitors in Asians were consistent with those in the whole study population. There were 4 trials for GLP-1RAs, including LEADER (51), HARMONY (52), SUSTAIN-6 (53), and REWIND (54); 9 trials for SGLT2 inhibitors, including EMPA-REG OUTCOME (55), CANVAS Program (56), DECLARE-TIMI 58 (57), CREDENCE (58), DAPA-CKD (22), the SCORED (23), DAPA-HF (60), EMPEROR-Reduced (21), and SOLOIST-WHF (24). CI = confidence interval; EP = end point; GLP-1RA = glucagon-like peptide 1 receptor agonist; HF = heart failure; MACE = major adverse cardiovascular events; NA = not available; SGLT2 = sodium-glucose cotransporter 2.

HHS Vulnerability Disclosure